LataMed AI Eyes Global Expansion at World Health Expo 2027

LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, has announced its planned attendance at the World Health Expo 2027 in Dubai as part of a broader strategy to evaluate international healthcare expansion opportunities beyond its current Latin American focus. The company, which specializes in telehealth infrastructure, healthcare analytics, and care coordination solutions for emerging markets, believes that participation in this global event will allow it to engage with healthcare leaders, technology innovators, and potential strategic partners. Management sees this as a key step in assessing international commercialization opportunities for its digital healthcare ecosystem, which includes telehealth infrastructure, healthcare coordination technologies, pharmacy integration, insurance accessibility solutions, and AI-driven platforms.

The planned attendance follows recent international engagement initiatives, including participation at HLTH Europe, and complements ongoing expansion throughout Latin America, particularly in Venezuela and Colombia. Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the importance of evaluating opportunities beyond existing markets to support the continued development and international expansion of the LataMed AI platform. However, management noted that attendance remains in the planning stage, and no assurance can be provided regarding the completion of any strategic relationships or agreements that may arise.

In addition to the World Health Expo plans, LataMed AI announced that its 5-for-1 forward stock split and mandatory share exchange are expected to become effective on July 15, 2026, pending FINRA processing. Shareholders holding shares through brokerage accounts generally need not take action, while those with physical certificates must exchange them through the transfer agent. The company looks forward to completing this corporate milestone as it focuses on expanding its telemedicine platform and commercializing its AI platforms, including CardioAI, PulmoAI, and NeuroAI. For more details, visit the company's website at https://latamed.ai.